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Abstract
Context: Bilirubin has been shown to influence the mechanisms of both apoptosis and inflammation.
Aims: The aim of the following study is to investigate the relationship between the serum bilirubin level with sepsis 
progression.
Settings and Design: A total of 20 patients from intensive care unit were included for this study.
Materials and Methods: Patients were divided into two groups: Patients diagnosed with sepsis according to the 
American College of Chest Physicians/Society of Clinical Care Medicine consensus conference criteria (n = 10) and 
patients treated for various other diagnoses (n = 10). Blood samples were collected for both groups at the time of origin 
(defined as the time of diagnosis) and 24 and 48 h after diagnosis. Serum interleukin (IL)‑6, IL‑10 and bilirubin levels 
were analyzed and compared. Acute physiology and chronic health evaluation (APACHE) II and sepsis related organ 
failure (SOFA) scores of the patients were also evaluated.
Statistical Analysis Used: We used Statistical Package for Social Sciences (SPSS for Windows, version 17.0, SPSS 
Inc. 233 South Wacker Drive, Chicago) for statistical analysis.
Results: At all‑time intervals, serum IL‑6, IL‑10 and total, direct and indirect serum bilirubin levels were significantly 
higher in the sepsis group (P < 0.05); APACHE II and SOFA scores were also significantly higher. Both SOFA scores 
and serum IL‑10 levels were positively correlated with bilirubin levels 24 h after diagnosis (P < 0.05, r = −0.76).
Conclusions: Although levels of bilirubin and other associated parameters were higher for the sepsis group, only 
SOFA score and bilirubin levels were correlated. Because bilirubin is already a SOFA parameter, this correlation was 
not considered as clinically significant.
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Introduction
Sepsis is a life‑threatening condition that arises when the 
body’s response to an infection injures its own tissues and 
organs. Sepsis may lead to shock, multiple organ failure and 
death, especially if not recognized early and treated promptly. 
Sepsis remains the primary cause of death from infection 
despite advances in modern medicine.[1] Therefore, sensitive 
and specific laboratory tests are needed to guide clinicians in 
achieving early diagnoses, monitoring therapeutic responses 
and developing treatment models if necessary.
Bilirubin is one of the end‑products of heme catabolism 
and occurs as a result of the activity of heme oxygenase 
and bilirubin reductase.[2] The relationship between 
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bilirubin and sepsis is not clear, but hemolysis, cholestasis 
and hepatic dysfunction may cause hyperbilirubinemia in 
septic patients. Impaired absorption, transport and clearance 
of bilirubin, as well as, hepatic and hepatocellular injury 
cause hepatic dysfunction. In sepsis, hypotension and 
reduced hepatic blood flow cause Kupffer cell dysfunction, 
ischemia (particularly cells in central zones) and subsequent 
damage with reperfusion.[3]
In patients with acute respiratory distress syndrome induced 
sepsis, hyperbilirubinemia is associated with poor prognosis 
and mortality. Previous studies found that the 1‑week 
mortality rate was significantly higher in these patients.[4,5] 
However, in one study,[5] clinical factors may have influenced 
serum bilirubin levels.
Bilirubin suppresses post‑ischemic myocardial dysfunction, 
has a negative correlation with insulin resistance and 
type 2 diabetes and has protective effects against 
lipopolysaccharide (LPS) induced hepatic injury. Bilirubin 
also improves carrageenan‑induced local inflammation 
and vascular endothelial cell adhesion molecule (VCAM) 
related airway inflammation and blocks VCAM‑1 
dependent lymphocyte migration. These findings suggest 
that bilirubin is a cytoprotective molecule.[6‑9] However, 
recent studies have reported that bilirubin is associated 
with apoptosis and inflammation, both mechanisms 
related to sepsis pathogenesis. Bilirubin is known to induce 
apoptosis via mitochondrial pathways and activation of 
N‑Methyl‑D‑aspartate receptors.[10,11] Previous studies have 
also suggested that bilirubin has a negative correlation with 
C‑reactive protein levels and may inhibit the expression 
of inducible nitric oxide, as well as, the secretion of 
phospholipase A2 and NO; therefore, bilirubin may have 
anti‑inflammatory effects.[8,12,13]
Bilirubin levels may be useful in demonstrating progression 
from systemic inflammatory response syndrome to severe 
sepsis. Therefore, the present study investigates bilirubin, 
which is known to have apoptotic, anti‑inflammatory and 
anti‑oxidant properties and its association with serum 
interleukin (IL)‑6, IL‑10 and scores measuring patient 
morbidity and mortality.
Materials and Methods
After receiving approval from the faculty ethics committee, 
20 intensive care unit (ICU) patients diagnosed with 
sepsis or other diseases and between the ages of 18 
and 75, were included. All patients were receiving 
synchronized intermittent mechanical ventilation (tidal 
volume: 6‑8 ml/kg, f: 12‑14, I/E: 1/2). Informed consent 
was obtained from the patients’ relative. The patients 
were classified into two groups: Patients diagnosed 
with sepsis according to the American College of Chest 
Physicians/Society of Clinical Care Medicine consensus 
conference criteria (n = 10); and patients treated for other 
reasons (n = 10). Patients with a history of hepatobiliary 
diseases, jaundice, hepatitis B virus/hepatitis C virus sero 
positivity, renal failure, drug overdose, hemolytic anemia, 
hypoxia, severe hemodynamic instability and/or possible 
brain death were excluded.
Blood samples were taken at 3 time intervals: The time of 
origin (defined as the day of sepsis diagnosis), 24 and 48 h 
after diagnosis. Serum IL‑6, IL‑10 and total, direct and 
indirect bilirubin levels were evaluated; acute physiology 
and chronic health evaluation (APACHE) II and sepsis 
related organ failure (SOFA) scores were also evaluated.
Blood samples were centrifuged at 3000/rpm for 5 min 
and then kept at −80°C. Human IL‑6 and IL‑10 
commercial kits (Invitrogen, California, USA) and fully 
automated enzyme‑linked immunosorbent assay Dynex 
Technologies Headquarters 14340 Sullyfield Circle 
Chantilly, VA 20151‑1621 USA) were used for IL‑6 and 
IL‑10 measurements (pg/ml). To determine bilirubin levels, 
rapidlab 348 (Siemens, Chapel Lane Swords County Dublin, 
Ireland) was used (mg/ml).
We used Statistical Package for Social Sciences (SPSS for 
Windows, version 17.0) for statistical analysis. Findings 
were described as median (min‑max). The Wilcoxon 
Signed Rank Test was used for comparison within groups. 
Gender was evaluated by Fisher’s‑Exact, Chi‑Square test. 
For comparing between groups, the Mann Whitney U‑test 
was used. To identify correlations, Pearson’s and Spearman’s 
correlation tests were performed. P < 0.05 were considered 
to be significant.
Results
The demographic characteristics of the patients were not 
statistically different. In the sepsis group, five patients had 
urosepsis, three had sepsis following abdominal infection 
and two patients had pulmonary origin [Table 1].
Within the groups, serum IL‑6 levels were not statistically 
different for all time intervals [Tables 2 and 3]. Serum 
IL‑10 levels were not statistically different for different time 
intervals [Tables 2 and 3]. However, serum IL‑6 levels were 
higher in the sepsis group compared to the control group 
at all‑time intervals (respectively, P = 0.008, P = 0.005 
and P = 0.041) [Figure 1]. Serum IL‑10 levels were higher 
in the sepsis group compared with the control group at 
all‑time intervals (respectively, P = 0.001, P = 0.028 and 
P = 0.029) [Figure 2]. Serum total and direct bilirubin levels 
were higher in the sepsis group compared to the control 
group at all‑time intervals (P = 0.001) [Figure 3], indirect 
bilirubin levels were higher in the sepsis group compared 
to the control group at all‑time intervals (respectively, 
P = 0.001, P = 0.002 and P = 0.001).
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Patients with sepsis had higher APACHE II compared to 
the control group (P = 0.001) [Figure 4]. SOFA scores 
also had higher in the sepsis group compared to the control 
group (P = 0.001) [Figure 5 and Table 4]. Serum IL‑10 levels 
and SOFA scores of septic patients were correlated 24 h 
after diagnosis (r = −0.76, P = 0.01). Only SOFA scores 
were correlated with serum total bilirubin levels (r = 0.72, 
P = 0.017) and serum direct bilirubin (r = 0.74, P < 0.014) 
24 h after diagnosis.
Discussion
Bilirubin can be measured by performing routine biochemical 
tests in ICU and other units; measurement is thought 
to aid in early diagnosis of sepsis and to provide some 
information about clinical progression and prognosis. 
Therefore, we investigated the association between sepsis 
and hyperbilirubinemia and also between hyperbilirubinemia 
and APACHE II and SOFA scores in septic patients without 
primary hepatobiliary diseases.
Experimental and clinical studies have found increased 
serum and tissue IL‑6 and IL‑10 levels and strong 
correlations between plasma IL‑10 levels and APACHE II 
and multiple organ dysfunction scores. Plasma IL‑6 levels 
have also been shown to have predictive value for sepsis 
survival.[14‑17] Similarly, we found that IL‑6 and IL‑10 levels 
were higher in the sepsis group compared to the control 
group.
In one study, the authors injected LPS to subjects and 
created a sepsis model to investigate the relationship 
between infection and bilirubin. At 18 h after LPS 
injection, sinusoidal uptake, hepatic concentration 
and canalicular excretion of bilirubin were lower in 
endotoxemic groups compared to control groups.[18] In a 
study of 19 patients with intraabdominal infection but no 
primary hepatobiliary diseases, total bilirubin levels were 
substantially higher 12 h after diagnosis in patients with 
septic shock.[19] Our findings were consistent with these 
studies. In our study, sepsis patients had hyperbilirubinemia 
24 h after diagnosis.
High bilirubin levels may indicate a poor prognosis; 
however, recent studies suggest a negative correlation 
between bilirubin levels and atherosclerosis and ischemic 
heart disease and it is observed that patients with high 
billirubin levels had less atherosclerotic events than 
patients with normal bilirubin levels.[4,5,20,21] Two clinical 
studies have investigated the association between bilirubin 
levels and certain diseases that may cause morbidity in 
Table 1: Demographic data of patients
Groups Median (minimum-maximum) Statistical 
analysis 
(P)
Group control Group sepsis
Age (year) 72 (18‑75) 69 (19‑75) 0.53
Gender (F/M) 6/4 5/5 1.00
The number of 
patients treated with 
mechanical ventilation
10/10 10/10
Cause of admission to 
intensive care unit

















Table 2: Comparison of data according to baseline values
Group Median (minimum-maximum) Baseline (P)
Variable Baseline 24 h 48 h 24 h 48 h
Control IL‑6 4.70 (1.83‑13.75) 5.40 (3.20‑13.32) 6.75 (2.27‑18.00) 0.49 0.40
IL‑10 3.55 (1.20‑5.34) 4.10 (1.30‑5.80) 3.60 (1.43‑5.70) 0.66 0.53
T. Bil 0.56 (0.25‑1.06) 0.79 (0.07‑0.98) 0.71 (0.30‑1.00) 0.14 0.06
Sepsis IL‑6 43.73 (35.06‑248.32) 43.21 (26.02‑250.98) 39.78 (23.43‑412.00) 0.58 0.22
IL‑10 26.18 (10.19‑57.95) 17.75 (10.81‑147.13) 15.46 (10.32‑145.97) 0.71 0.72
T. Bil 1.88 (1.38‑2.60) 1.93 (1.40‑4.12) 1.96 (1.42‑5.03) 0.14 0.22
IL=Interleukin; T. Bil=Total bilirubin
Figure 1: Serum interleukin-6 levels
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neonates with low birth weight. Bilirubin levels were found 
to be lower in patients with retinopathy of prematurity, 
intraventricular hemorrhage, necrotizing enterocolitis, 
respiratory distress syndrome and bronchopulmonary 
dysplasia. Bilirubin was also thought to have anti‑oxidant 
effects.[22,23]
Rodrigues et al.[10] prepared neuron cultures taken from 17 
to 18 day old rat fetuses and administrated unconjugated 
bilirubin to evaluate the effect of bilirubin on apoptosis. 
In neurons exposed to bilirubin, excessive secretion of 
cytochrome c from the mitochondria and its accumulation 
in the cytosol were observed. It was also observed that 
even small increments in bilirubin levels activated 
caspase‑3 and caused full length substrate poly (ADP) 
Table 3: Comparison of percentage change compared 
to baseline values
Variable Median (minimum-maximum) P
Group control Group sepsis
IL‑6
0‑24 h 0.62 (0.05‑2.31) 0.08 (0.02‑2.31) 0.07
0‑48 h 0.65 (0.14‑3.47) 0.16 (0.01‑0.78) 0.02
IL‑10
0‑24 h 0.43 (0.00‑3.59) 0.44 (0.13‑3.08) 0.55
0‑48 h 0.48 (0.28‑3.50) 0.30 (0.16‑3.05) 0.44
T. Bil
0‑24 h 0.46 (0.07‑0.94) 0.09 (0.03‑0.96) 0.64
0‑48 h 0.21 (0.05‑0.55) 1.15 (0.02‑1.39) 0.95
IL=Interleukin; T. Bil=Total bilirubin
Table 4: Comparison of score change compared to 
baseline values
Variable Median (minimum-maximum) P
Group control Group sepsis
Acute physiology and 
chronic health evaluation
0‑24 h 0.5 (2‑3) 1.5 (1‑4) 0.12
0‑48 h 1 (2‑5) 2.5 (2‑4) 0.92
Sepsis‑related organ 
failure assessment
0‑24 h 0 (0‑1) 0 (0‑1) 0.61
0‑48 h 1 (0‑1) 0.5 (0‑1) 0.66
Figure 3: Serum total bilirubin levels
Figure 5: Sepsis related organ failure scores
Figure 2: Serum interleukin-10 levels
Figure 4: Acute physiology and chronic health evaluation scores
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ribose polymerase degradation. In another experimental 
study, exogenous bilirubin was shown to block VCAM‑1 
dependent lymphocyte migration via suppression of free 
oxygen radicals; it was also shown to improve VCAM related 
in vivo airway inflammation.[9]
Previous studies have also reported that high bilirubin levels 
reduce endotoxin‑induced inflammation, NO production 
via inhibition of nicotinamide adenine dinucleotide 
phosphate oxidase, microvascular leukocyte adhesion and 
pulmonary VCAM‑1 dependent leukocyte migration.[8,9,24,25] 
In subjects with experimental endotoxemia, administration 
of exogenous bilirubin improved clinical outcomes and also 
inhibited LPS‑induced leukocyte‑endothelial interaction 
and leukocyte accumulation. Moreover, gene expression 
of endothelial adhesion molecules and inflammatory 
mediators, such as IL‑1 β and tumor necrosis factor‑α, 
decreased significantly; thus, bilirubin has been suggested 
to have anti‑inflammatory effects.[26] In our study, no 
correlation was found between bilirubin levels and IL‑6 and 
IL‑10 levels in septic patients, perhaps due to the lack of 
long‑term, molecular follow up for inflammation. To the best 
of our knowledge, there is no other study that investigates 
the relationship between bilirubin and cytokine levels and 
hence this aspect of our study cannot be discussed.
APACHE II and SOFA scores are commonly used in ICUs 
to determine prognosis and mortality of patients with 
sepsis. APACHE II score is calculated the 12 physiological 
variables: (Age, temperature, mean arterial pressure, pH 
arterial, heart rate, respiratory rate, sodium, potassium, 
creatinine, hematocrit, white blood cell count, Glasgow 
Coma Scale). The SOFA was developed in 1994 during 
a consensus conference. Six organ systems (respiratory, 
cardiovascular, renal, hepatic, central nervous, coagulation) 
were selected based on a review of the literature and the 
function of each is scored from 0 (normal function) to 
4 (most abnormal), giving a possible score of 0‑24.[27] 
APACHE II and SOFA scores were higher in the sepsis 
group, as is consistent with the literature. Studies have 
reported that there is a correlation between APACHE 
II and SOFA scores and IL‑6 and IL‑10.[28,29] We did not 
observe a similar correlation in our study, perhaps due to 
the use of different sampling time intervals and the shorter 
duration of our study (48 h). Studies have suggested that 
the correlation between IL‑6 and APACHE II and III occurs 
3‑7 days after diagnosis of sepsis, or 1 day after severe sepsis. 
The correlation between IL‑10 and APACHE scores occurs 
within 1‑3 days after the onset of severe sepsis.[29‑31] A study 
by Oda et al.[32] evaluated IL‑6 levels of patients with SIRS 
and sepsis and reported that peak IL‑6 levels correlated 
with maximal SOFA levels. However, SOFA scores reached 
their maximum levels approximately 2.5 days after IL‑6 
levels peaked. Because our blood sampling intervals differed 
from literature, we did not find any correlation between 
SOFA scores and serum IL‑6 levels. However, we did find 
a correlation between SOFA scores and IL‑10 levels 24 h 
after diagnosis and this finding was consistent with the 
literature.[33] We also found a correlation between bilirubin 
levels and SOFA scores, but bilirubin is already a SOFA 
parameter, so this result was not considered clinically 
significant.
Bilirubin, a frequently used parameter in clinical units, is 
affected by hepatic infections and has a role in apoptosis 
and inflammation. We investigated whether bilirubin may 
be used in monitoring sepsis prognosis. We found that serum 
IL‑6 and IL‑10 levels, as well as APACHE II and SOFA 
scores, were significantly higher in patients with sepsis when 
compared with a control group, but no correlations between 
bilirubin and other important sepsis parameters were found. 
Our study has major limitations, including a small number 
of patients and failure to select a specific patient population 
for the control group. Therefore, further studies with larger 
populations and specific control groups are necessary.
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